We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Neostigmine for acute colonic pseudo-obstruction: A meta-analysis.
Annals of Medicine and Surgery 2014 September
INTRODUCTION: Acute colonic pseudo-obstruction (ACPO) is an uncommon condition that occasionally develops in hospitalized patients with serious underlying ailments. Its early recognition is essential to reduce life-threatening complications. Few low-powered randomized clinical trials (RCTs) have confirmed the effectiveness of neostigmine for treatment.
AIM: To analyse the effectiveness and main side effects of neostigmine in the treatment of ACPO.
EXPERIMENTAL: A literature search was performed for all published RCTs, reporting on neostigmine as treatment for ACPO.
RESULTS: Four studies fulfilled the inclusion criteria, evaluating 127 patients: treatment group = 65, control group = 62. Neostigmine effectiveness to resolve ACPO with only one dose was 89.2% versus 14.65% (P < 0.001, NNT = 1 [95% CI 1-2]).
CONCLUSIONS: Neostigmine is a safe and effective option for patients with ACPO who failed to respond to conservative management.
AIM: To analyse the effectiveness and main side effects of neostigmine in the treatment of ACPO.
EXPERIMENTAL: A literature search was performed for all published RCTs, reporting on neostigmine as treatment for ACPO.
RESULTS: Four studies fulfilled the inclusion criteria, evaluating 127 patients: treatment group = 65, control group = 62. Neostigmine effectiveness to resolve ACPO with only one dose was 89.2% versus 14.65% (P < 0.001, NNT = 1 [95% CI 1-2]).
CONCLUSIONS: Neostigmine is a safe and effective option for patients with ACPO who failed to respond to conservative management.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app